Patients with inflammatory bowel disease who switched from one infliximab biosimilar to another had no significant change in disease activity, according to research published in Alimentary Pharmacology and Therapeutics.

“Biological medicines account for a significant cost to health care systems in the management of IBD patients. However, since the expiration of patents for anti-tumor necrosis factor originators, biosimilars have offered the possibility of using cheaper alternatives with the potential for marked cost savings,” Raphael P. Luber, MBBS, FRACP, Guy’s and St. Thomas’

Full Article: